Daniel Michaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Michaud has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer L. Guerriero
Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, USA
17 shared publications - Binita Chakraborty
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
14 shared publications - Charles M. Perou
University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
14 shared publications - Ching-Yi Chang
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA
14 shared publications - Corinne Haines
Nationwide Children’s Hospital 1 Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute Columbus, Ohio
14 shared publications - Donald Patrick McDonnell
Duke University School of Medicine, Durham, North Carolina
14 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e014578
PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer
Background: Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies suggest that inhibition of PARP1 alone is sufficient to drive antitumor efficacy. In contrast, inhibition of PARP2 has been implicated in hematological toxicities seen in patients receiving PARPi therapy. Therefore, selectively inhibiting PARP1 may reduce toxicity for patients. Here, we characterize and test the PARP1-selective inhibitor DSB1559 in preclinical models of Brca1-associated triple-negative breast cancer (TNBC). Methods: Pharmacokinetic/pharmacodynamic assays were performed to examine DSB1559 potency, selectivity, and in vivo behavior. Immunocompetent FVB/n mice bearing Brca1-deficient TNBC (CMV-Cre;Brca1 fl/fl ;Trp53 fl/fl ) tumors were treated with olaparib or DSB1559 and followed for survival. Flow cytometry and bulk RNA-sequencing were performed to measure the effects on the tumor microenvironment (TME). Results: DSB1559 had superior selectivity for PARP1 and increased overall survival compared with olaparib. Analysis of the TME revealed a significant increase in cytotoxic T-cells, activated dendritic cells, and genes associated with antitumor immunity in mice treated with DSB1559. Conclusions: Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy and antitumor immune response compared with olaparib. A structurally related, clinical lead compound (DSB2455) is now being tested in a phase Ia/Ib clinical trial ( NCT06458712 ).
- 7 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e014578
Open AccessPARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer
Background: Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies suggest that inhibition of PARP1 alone is sufficient to drive antitumor efficacy. In contrast, inhibition of PARP2 has been implicated in hematological toxicities seen in patients receiving PARPi therapy. Therefore, selectively inhibiting PARP1 may reduce toxicity for patients. Here, we characterize and test the PARP1-selective inhibitor DSB1559 in preclinical models of Brca1-associated triple-negative breast cancer (TNBC). Methods: Pharmacokinetic/pharmacodynamic assays were performed to examine DSB1559 potency, selectivity, and in vivo behavior. Immunocompetent FVB/n mice bearing Brca1-deficient TNBC (CMV-Cre;Brca1 fl/fl ;Trp53 fl/fl ) tumors were treated with olaparib or DSB1559 and followed for survival. Flow cytometry and bulk RNA-sequencing were performed to measure the effects on the tumor microenvironment (TME). Results: DSB1559 had superior selectivity for PARP1 and increased overall survival compared with olaparib. Analysis of the TME revealed a significant increase in cytotoxic T-cells, activated dendritic cells, and genes associated with antitumor immunity in mice treated with DSB1559. Conclusions: Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy and antitumor immune response compared with olaparib. A structurally related, clinical lead compound (DSB2455) is now being tested in a phase Ia/Ib clinical trial ( NCT06458712 ).
- 29 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform that integrated IL-12 signaling to enhance antitumor immunity. IL-12 signaling synergized with CAR activation to sustain mTORC1 activity through convergent Ras-ERK and PI3K pathways, promoting metabolic fitness, autonomous expansion, and sustained effector function. IL-12 also activated bystander NK cells, T cells, and macrophages to remodel the tumor microenvironment. To improve safety, IL-12 was tethered to a collagen-binding A3-domain, restricting its activity to the extracellular matrix and limiting systemic exposure. In ovarian and pancreatic cancer models, matrix-anchored IL-12 CAR NK cells expanded without exogenous cytokines and achieved durable tumor control. These findings suggest that mTORC1-mediated integration of CAR and cytokine signaling can enhance immune fitness and overcome immunosuppressive tumor microenvironments.
- 29 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform that integrated IL-12 signaling to enhance antitumor immunity. IL-12 signaling synergized with CAR activation to sustain mTORC1 activity through convergent Ras-ERK and PI3K pathways, promoting metabolic fitness, autonomous expansion, and sustained effector function. IL-12 also activated bystander NK cells, T cells, and macrophages to remodel the tumor microenvironment. To improve safety, IL-12 was tethered to a collagen-binding A3-domain, restricting its activity to the extracellular matrix and limiting systemic exposure. In ovarian and pancreatic cancer models, matrix-anchored IL-12 CAR NK cells expanded without exogenous cytokines and achieved durable tumor control. These findings suggest that mTORC1-mediated integration of CAR and cytokine signaling can enhance immune fitness and overcome immunosuppressive tumor microenvironments.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Purpose:In advanced estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for treatment in the first-line setting. Although CDK4/6is were initially developed to induce cell-cycle arrest, it is evident that CDK4/6is also have the potential to regulate the tumor immune microenvironment. In this study, we characterize the baseline immune landscape and the immunomodulatory effects of abemaciclib and ET in advanced breast cancer tumors. Experimental Design:We used single-cell RNA sequencing of CD45-enriched cells to investigate the effect of the CDK4/6i, abemaciclib, and ET on the transcriptome of immune cell populations in 13 matched-pair advanced and metastatic estrogen receptor–positive/HER2− breast tumor biopsies. We tested the association of immune cell population gene signatures with survival in publicly available datasets. Results:We profiled 170,798 cells from bone, breast, lymph node, and liver biopsies. We found that the expression of genes associated with interferon response are downregulated in many T-cell populations. The expression of genes associated with antigen presentation was upregulated in tumor-associated macrophages (TAM) and dendritic cells after treatment. The relative proportion of TREM2+ TAMs decreases after treatment with abemaciclib and ET in late progressors, and lower expression of the TREM2+ TAM signature is associated with improved overall survival (OS) in patients with breast cancer. Conclusions:Our data reveal heterogeneous lymphoid and myeloid subpopulations in advanced and metastatic breast tumors that are associated with late progression on abemaciclib and ET and OS in patients with breast cancer.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Purpose:In advanced estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for treatment in the first-line setting. Although CDK4/6is were initially developed to induce cell-cycle arrest, it is evident that CDK4/6is also have the potential to regulate the tumor immune microenvironment. In this study, we characterize the baseline immune landscape and the immunomodulatory effects of abemaciclib and ET in advanced breast cancer tumors. Experimental Design:We used single-cell RNA sequencing of CD45-enriched cells to investigate the effect of the CDK4/6i, abemaciclib, and ET on the transcriptome of immune cell populations in 13 matched-pair advanced and metastatic estrogen receptor–positive/HER2− breast tumor biopsies. We tested the association of immune cell population gene signatures with survival in publicly available datasets. Results:We profiled 170,798 cells from bone, breast, lymph node, and liver biopsies. We found that the expression of genes associated with interferon response are downregulated in many T-cell populations. The expression of genes associated with antigen presentation was upregulated in tumor-associated macrophages (TAM) and dendritic cells after treatment. The relative proportion of TREM2+ TAMs decreases after treatment with abemaciclib and ET in late progressors, and lower expression of the TREM2+ TAM signature is associated with improved overall survival (OS) in patients with breast cancer. Conclusions:Our data reveal heterogeneous lymphoid and myeloid subpopulations in advanced and metastatic breast tumors that are associated with late progression on abemaciclib and ET and OS in patients with breast cancer.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S8. Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each myeloid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S8. Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each myeloid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S4. A) Box plot of IFNG expression at T1 and T2 for each T cell cluster grouped by response. Median expression is indicated by green line. Statistical significance determined by two-way ANOVA with post-hoc Tukey-HSD test. *p.adjust £ 0.05. B) Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each lymphoid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S4. A) Box plot of IFNG expression at T1 and T2 for each T cell cluster grouped by response. Median expression is indicated by green line. Statistical significance determined by two-way ANOVA with post-hoc Tukey-HSD test. *p.adjust £ 0.05. B) Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each lymphoid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S2. Patient characteristics and number of cells analyzed. Supplementary Table S3. Marker genes for each cluster Supplementary Table S4. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between response groups. Supplementary Table S5. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between metastatic sites. Supplementary Table S6. Top 50 Marker genes for each lymphoid cluster Supplementary Table S7. Genes used for pathway signatures retrieved from MSigDB. Supplementary Table S8. Genes differentially expressed between lymphoid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S9. Top 50 Marker genes for each myeloid cluster Supplementary Table S10. Genes differentially expressed between myeloid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S11. Genes differentially expressed between myeloid clusters 1, 5, and 7. Supplementary Table S12. Genes used for survival analyses. Genes were selected by using a max pvalue cutoff of 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S2. Patient characteristics and number of cells analyzed. Supplementary Table S3. Marker genes for each cluster Supplementary Table S4. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between response groups. Supplementary Table S5. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between metastatic sites. Supplementary Table S6. Top 50 Marker genes for each lymphoid cluster Supplementary Table S7. Genes used for pathway signatures retrieved from MSigDB. Supplementary Table S8. Genes differentially expressed between lymphoid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S9. Top 50 Marker genes for each myeloid cluster Supplementary Table S10. Genes differentially expressed between myeloid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S11. Genes differentially expressed between myeloid clusters 1, 5, and 7. Supplementary Table S12. Genes used for survival analyses. Genes were selected by using a max pvalue cutoff of 0.05.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S6. A) UMAP visualization of myeloid cell type markers for macrophages (CD68), M2-like macrophages (CD163), antigen-presenting cells (HLA-DRA), monocytes (CD14), dendritic cells (CD1C), and mast cells (KIT). B) Relative proportions of myeloid clusters per patient per timepoint per metastasis site. C) Relative proportions of myeloid clusters per patient per timepoint per response group.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S6. A) UMAP visualization of myeloid cell type markers for macrophages (CD68), M2-like macrophages (CD163), antigen-presenting cells (HLA-DRA), monocytes (CD14), dendritic cells (CD1C), and mast cells (KIT). B) Relative proportions of myeloid clusters per patient per timepoint per metastasis site. C) Relative proportions of myeloid clusters per patient per timepoint per response group.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S7. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average log2FC where a positive value indicates the gene was more highly expressed at T2. * FDR £ 0.05. UMAP visualization of hormone receptor genes, ESR1, ESR2, GPER1, PGR and AR and ER target genes, GREB1 and TFF1 in myeloid clusters split by timepoint.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S7. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average log2FC where a positive value indicates the gene was more highly expressed at T2. * FDR £ 0.05. UMAP visualization of hormone receptor genes, ESR1, ESR2, GPER1, PGR and AR and ER target genes, GREB1 and TFF1 in myeloid clusters split by timepoint.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S1. Representativeness of Study Participants.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S1. Representativeness of Study Participants.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S2. A) UMAP visualization of lymphoid marker genes. B) Relative proportions of lymphoid clusters per patient per timepoint per metastasis site. C) Relative proportions of lymphoid clusters per patient per timepoint per response group.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S2. A) UMAP visualization of lymphoid marker genes. B) Relative proportions of lymphoid clusters per patient per timepoint per metastasis site. C) Relative proportions of lymphoid clusters per patient per timepoint per response group.